General Information of This Antibody (ID: ANTI0GYKVL)
Antibody Name
chMC-813-70
Organization
The Scripps Research Institute.; Academia Sinica.
Synonyms
chMC-813-70
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric lgG
Antigen Name
Stage-specific embryonic antigen-4 (SSEA4)
 Antigen Info 
Click to Show/Hide the Sequence Information of This Antibody
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
chMC-813-70-VC-PAB-MMAE [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.211 nM
Positive HER2 expression (HER2+++/++)
Method Description
Having ADCs with cleavable and non-cleavable linkers in place, we next assessed there in vitro cytotoxicity activities using SSEA4-expressing ovarian SKVO3 cells and breast cancer cells SKBR3 with a negligible expression of SSEA4 and 293T cells as a control. SK-OV3, SKBR3, and 293T cells (2×103 cells/well) were incubated with ADC-1, ADC-2, and chMC-813-70 for 72 h and then treated with MTS at 37 °C. The conversion of the tetrazolium salt MTS (3- (4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium) to a purple formazan, as a measure of the percentage of viable cells, was measured by absorbance at 490 nm after 4 h. The untreated cells' absorbance was considered 100 % survival (Figure 4).

   Click to Show/Hide
In Vitro Model Ovarian serous adenocarcinoma SKOV-3 cells CVCL_0532
References
Ref 1 Probing the Internalization and Efficacy of Antibody-Drug Conjugate via Site-Specific Fc-Glycan Labelling of a Homogeneous Antibody Targeting SSEA-4 Bearing Tumors